CN109641844B - 整合应激通路的调节剂 - Google Patents

整合应激通路的调节剂 Download PDF

Info

Publication number
CN109641844B
CN109641844B CN201780042069.2A CN201780042069A CN109641844B CN 109641844 B CN109641844 B CN 109641844B CN 201780042069 A CN201780042069 A CN 201780042069A CN 109641844 B CN109641844 B CN 109641844B
Authority
CN
China
Prior art keywords
alkyl
formula
independently
compound
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780042069.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN109641844A (zh
Inventor
C.西德劳斯基
M.普利什切夫
J.M.弗罗斯特
L.A.布莱克
X.许
R.F.斯韦斯
L.石
Q.I.张
Y.童
C.W.哈钦斯
S.郑
M.J.达特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Calico Life Sciences LLC
Original Assignee
AbbVie Inc
Calico Life Sciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc, Calico Life Sciences LLC filed Critical AbbVie Inc
Priority to CN202211242583.XA priority Critical patent/CN115947681B/zh
Publication of CN109641844A publication Critical patent/CN109641844A/zh
Application granted granted Critical
Publication of CN109641844B publication Critical patent/CN109641844B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
    • C07C235/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/23—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms
    • C07C311/24—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C07D213/66—One oxygen atom attached in position 3 or 5 having in position 3 an oxygen atom and in each of the positions 4 and 5 a carbon atom bound to an oxygen, sulphur, or nitrogen atom, e.g. pyridoxal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C07D237/16—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/64—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/38—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing five carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/40—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing six carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/44—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing eight carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/90—Ring systems containing bridged rings containing more than four rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
CN201780042069.2A 2016-05-05 2017-05-05 整合应激通路的调节剂 Active CN109641844B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211242583.XA CN115947681B (zh) 2016-05-05 2017-05-05 整合应激通路的调节剂

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662332278P 2016-05-05 2016-05-05
US62/332,278 2016-05-05
PCT/US2017/031360 WO2017193034A1 (en) 2016-05-05 2017-05-05 Modulators of the integrated stress pathway

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202211242583.XA Division CN115947681B (zh) 2016-05-05 2017-05-05 整合应激通路的调节剂

Publications (2)

Publication Number Publication Date
CN109641844A CN109641844A (zh) 2019-04-16
CN109641844B true CN109641844B (zh) 2022-11-01

Family

ID=58709639

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780042069.2A Active CN109641844B (zh) 2016-05-05 2017-05-05 整合应激通路的调节剂
CN202211242583.XA Active CN115947681B (zh) 2016-05-05 2017-05-05 整合应激通路的调节剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202211242583.XA Active CN115947681B (zh) 2016-05-05 2017-05-05 整合应激通路的调节剂

Country Status (38)

Country Link
US (3) US20190144440A1 (enExample)
EP (2) EP3452448B1 (enExample)
JP (4) JP6997766B2 (enExample)
KR (3) KR102512049B1 (enExample)
CN (2) CN109641844B (enExample)
AR (1) AR110599A1 (enExample)
AU (3) AU2017260367B2 (enExample)
BR (1) BR112018072663A2 (enExample)
CA (1) CA3023162A1 (enExample)
CL (1) CL2018003142A1 (enExample)
CO (1) CO2018012946A2 (enExample)
CR (2) CR20210372A (enExample)
DK (1) DK3452448T3 (enExample)
DO (1) DOP2018000242A (enExample)
EC (1) ECSP18089579A (enExample)
ES (1) ES2973442T3 (enExample)
FI (1) FI3452448T3 (enExample)
HR (1) HRP20240218T1 (enExample)
HU (1) HUE065713T2 (enExample)
IL (3) IL286693B2 (enExample)
LT (1) LT3452448T (enExample)
MA (1) MA44861B1 (enExample)
MD (1) MD3452448T2 (enExample)
MX (2) MX2021007146A (enExample)
MY (1) MY200943A (enExample)
PE (2) PE20231935A1 (enExample)
PH (1) PH12018502329B1 (enExample)
PL (1) PL3452448T3 (enExample)
PT (1) PT3452448T (enExample)
RS (1) RS65214B1 (enExample)
RU (2) RU2769327C2 (enExample)
SG (1) SG11201809695TA (enExample)
SI (1) SI3452448T1 (enExample)
SM (1) SMT202400098T1 (enExample)
TW (3) TWI920577B (enExample)
UA (1) UA125513C2 (enExample)
UY (2) UY40873A (enExample)
WO (1) WO2017193034A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI920577B (zh) * 2016-05-05 2026-04-01 美商嘉來克生命科學有限責任公司 整合應激途徑之調節劑
CN110730777A (zh) * 2017-06-07 2020-01-24 葛兰素史密斯克莱知识产权发展有限公司 作为atf4通路抑制剂的化学化合物
WO2019008506A1 (en) * 2017-07-03 2019-01-10 Glaxosmithkline Intellectual Property Development Limited N- (3- (2- (4-CHLOROPHENOXY) ACETAMIDO) BICYCLO [1.1.1] PENTAN-1-YL) -2-CYCLOBUTANE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ATF4 INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER DISEASES
IL301709B2 (en) * 2017-08-09 2025-07-01 Denali Therapeutics Inc Compounds, compositions and methods
TW201920129A (zh) 2017-09-01 2019-06-01 美商戴納立製藥公司 化合物、組合物及方法
UY37956A (es) * 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
JP2021501785A (ja) 2017-11-02 2021-01-21 カリコ ライフ サイエンシーズ エルエルシー 統合的ストレス経路の調節剤
UY37958A (es) * 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
JP2021508336A (ja) 2017-12-13 2021-03-04 プラクシス バイオテック エルエルシー 統合的ストレス応答経路の阻害剤
WO2019183589A1 (en) * 2018-03-23 2019-09-26 Denali Therapeutics Inc. Modulators of eukaryotic initiation factor 2
US11166942B2 (en) 2018-06-05 2021-11-09 Praxis Biotech LLC Inhibitors of integrated stress response pathway
JP2021529814A (ja) * 2018-07-09 2021-11-04 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 化学化合物
TW202545902A (zh) * 2018-10-11 2025-12-01 美商嘉來克生命科學有限責任公司 整合應激路徑之前藥調節劑
EP3924341A4 (en) 2019-02-13 2022-11-02 Denali Therapeutics Inc. Compounds, compositions and methods
CR20210426A (es) 2019-02-13 2021-09-30 Denali Therapeutics Inc Compuestos, composiciones y métodos
SG11202107871UA (en) * 2019-02-25 2021-08-30 Praxis Biotech LLC Inhibitors of integrated stress response pathway
MX2021012904A (es) 2019-04-23 2022-01-18 Evotec Int Gmbh Moduladores de la via de respuesta al estres integrada.
WO2020216766A1 (en) 2019-04-23 2020-10-29 Evotec International Gmbh Modulators of the integrated stress response pathway
PH12021552759A1 (en) * 2019-04-30 2022-07-04 Abbvie Inc Substituted cycloalkyls as modulators of the integrated stress pathway
AR118836A1 (es) * 2019-04-30 2021-11-03 Calico Life Sciences Llc Moduladores de la vía de tensión integrada
JP2022536663A (ja) 2019-06-12 2022-08-18 プラクシス バイオテック エルエルシー 統合的ストレス応答経路のモジュレーター
PH12022551379A1 (en) * 2019-12-06 2023-05-03 Vertex Pharma Substituted tetrahydrofurans as modulators of sodium channels
CA3162526A1 (en) 2020-01-28 2021-08-05 Christopher John Brown Modulators of the integrated stress response pathway
KR20220151635A (ko) 2020-03-11 2022-11-15 에보텍 인터내셔널 게엠베하 통합 스트레스 반응 경로의 조절제
EP4178955A1 (en) 2020-07-11 2023-05-17 Pfizer Inc. Antiviral heteroaryl ketone derivatives
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
MX2023004677A (es) 2020-10-22 2023-05-24 Evotec Int Gmbh Moduladores de la via de respuesta integrada al estres.
ES2997335T3 (en) 2020-10-22 2025-02-17 Evotec Int Gmbh Modulators of the integrated stress response pathway
CA3195290A1 (en) 2020-10-22 2022-04-28 Holly Victoria Atton Modulators of the integrated stress response pathway
EP4259132A4 (en) * 2020-12-10 2025-01-15 Adgero Biopharmaceuticals Holdings, Inc. METHODS OF TREATMENT OF METASTATIC SKIN CANCER
TW202241857A (zh) 2020-12-18 2022-11-01 美商戴納立製藥公司 化合物之固體形式
KR102992203B1 (ko) * 2024-02-05 2026-07-20 재단법인 대구경북첨단의료산업진흥재단 신규한 eIF2B 작용제 및 이를 포함하는 대사질환 예방 또는 치료용 조성물
WO2025255324A1 (en) * 2024-06-06 2025-12-11 Lapis Therapeutics, Inc. Inhibitors of lipoprotein(a) assembly

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1906169A (zh) * 2004-01-07 2007-01-31 阿斯利康(瑞典)有限公司 治疗剂i
CN101282928A (zh) * 2005-08-08 2008-10-08 阿金塔探索有限公司 二环[2.2.1]庚-7-基胺衍生物及其用途
CN103369961A (zh) * 2010-12-22 2013-10-23 H.隆德贝克有限公司 双环[3.2.1]辛基酰胺衍生物及其用途
WO2015038778A1 (en) * 2013-09-11 2015-03-19 The Brigham And Women's Hospital, Inc. SUBSTITUTED UREA EIF2α KINASE ACTIVATORS
US20160096800A1 (en) * 2013-03-15 2016-04-07 The Regents Of The University Of California Modulators of the eif2alpha pathway

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US162A (en) 1837-04-17 Island
US5212A (en) 1847-07-31 Richard m
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US20070185079A1 (en) * 2004-01-07 2007-08-09 Astrazeneca Ab Therapeutic agents I
EP1794120B1 (en) * 2004-07-23 2012-04-11 Nuada, LLC Peptidase inhibitors
RU2442771C2 (ru) * 2005-08-08 2012-02-20 Арджента Дискавери Лтд Производные бицикло[2,2,1]гепт-7-иламина и их применения
WO2007017752A1 (en) 2005-08-10 2007-02-15 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
BRPI0817315A2 (pt) * 2007-09-25 2015-03-17 Takeda Pharmaceutical Inibidores de quinase do tipo polo
MX336559B (es) * 2010-03-17 2016-01-25 Axikin Pharmaceuticals Inc Antagonistas de ccr3 de arilsulfonamida.
ES2570177T3 (es) * 2010-08-10 2016-05-17 Astellas Pharma Inc Compuesto heterocíclico
MX358346B (es) * 2014-04-04 2018-08-15 Syros Pharmaceuticals Inc Inhibidores de la quinasa dependiente de ciclina 7 (cdk7).
TWI920577B (zh) * 2016-05-05 2026-04-01 美商嘉來克生命科學有限責任公司 整合應激途徑之調節劑

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1906169A (zh) * 2004-01-07 2007-01-31 阿斯利康(瑞典)有限公司 治疗剂i
CN101282928A (zh) * 2005-08-08 2008-10-08 阿金塔探索有限公司 二环[2.2.1]庚-7-基胺衍生物及其用途
CN103369961A (zh) * 2010-12-22 2013-10-23 H.隆德贝克有限公司 双环[3.2.1]辛基酰胺衍生物及其用途
US20160096800A1 (en) * 2013-03-15 2016-04-07 The Regents Of The University Of California Modulators of the eif2alpha pathway
WO2015038778A1 (en) * 2013-09-11 2015-03-19 The Brigham And Women's Hospital, Inc. SUBSTITUTED UREA EIF2α KINASE ACTIVATORS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Chemically Induced Cardiomyogenesis of Mouse Embryonic Stem Cells;Albrecht Berkessel et al.;《ChemBioChem》;20091218;第11卷;第208-217页 *

Also Published As

Publication number Publication date
MY200943A (en) 2024-01-24
UA125513C2 (uk) 2022-04-13
MX383652B (es) 2025-03-14
LT3452448T (lt) 2024-03-12
JP2022046578A (ja) 2022-03-23
RU2018142740A (ru) 2020-06-05
JP2019515043A (ja) 2019-06-06
IL323840A (en) 2025-12-01
IL262722B (en) 2021-10-31
EP4356971A3 (en) 2024-07-24
MA44861A (fr) 2019-03-13
SMT202400098T1 (it) 2024-05-14
TWI920577B (zh) 2026-04-01
TW201808887A (zh) 2018-03-16
AU2024227527A1 (en) 2024-11-14
HUE065713T2 (hu) 2024-06-28
PE20231935A1 (es) 2023-12-05
CR20180574A (es) 2019-05-15
IL286693B1 (en) 2025-11-01
JP6997766B2 (ja) 2022-01-20
US20250122188A1 (en) 2025-04-17
RS65214B1 (sr) 2024-03-29
EP4356971A2 (en) 2024-04-24
CA3023162A1 (en) 2017-11-09
SG11201809695TA (en) 2018-11-29
AU2017260367B2 (en) 2021-12-02
TWI763668B (zh) 2022-05-11
NZ747842A (en) 2025-05-30
WO2017193034A1 (en) 2017-11-09
AU2022200946B2 (en) 2024-07-25
US20220363678A1 (en) 2022-11-17
US20190144440A1 (en) 2019-05-16
KR20250042188A (ko) 2025-03-26
MD3452448T2 (ro) 2024-04-30
CO2018012946A2 (es) 2019-08-20
IL286693A (en) 2021-10-31
KR102512049B1 (ko) 2023-03-21
JP2026009986A (ja) 2026-01-21
BR112018072663A2 (pt) 2019-02-19
UY37228A (es) 2017-11-30
PE20190348A1 (es) 2019-03-07
CN115947681B (zh) 2025-10-14
DOP2018000242A (es) 2019-04-15
CN109641844A (zh) 2019-04-16
AR110599A1 (es) 2019-04-17
MA44861B1 (fr) 2024-02-29
ES2973442T3 (es) 2024-06-20
FI3452448T3 (fi) 2024-03-19
DK3452448T3 (da) 2024-02-12
RU2018142740A3 (enExample) 2020-08-24
CR20210372A (es) 2022-06-07
JP2024023324A (ja) 2024-02-21
KR102781404B1 (ko) 2025-03-18
RU2769327C2 (ru) 2022-03-30
JP7755632B2 (ja) 2025-10-16
SI3452448T1 (sl) 2024-04-30
RU2022106770A (ru) 2022-04-05
HRP20240218T1 (hr) 2024-04-26
KR20190031203A (ko) 2019-03-25
IL262722A (en) 2018-12-31
PH12018502329B1 (en) 2023-08-11
TW202506629A (zh) 2025-02-16
AU2017260367A1 (en) 2018-11-22
CN115947681A (zh) 2023-04-11
PH12018502329A1 (en) 2019-03-25
ECSP18089579A (es) 2019-02-28
AU2022200946A1 (en) 2022-03-03
PL3452448T3 (pl) 2024-07-08
TWI844006B (zh) 2024-06-01
EP3452448B1 (en) 2023-12-20
KR20230042146A (ko) 2023-03-27
NZ787908A (en) 2025-05-30
MX2021007146A (es) 2022-11-29
IL286693B2 (en) 2026-03-01
TW202304851A (zh) 2023-02-01
JP7389786B2 (ja) 2023-11-30
CL2018003142A1 (es) 2019-05-24
UY40873A (es) 2024-09-13
EP3452448A1 (en) 2019-03-13
PT3452448T (pt) 2024-03-19
MX2018013495A (es) 2019-07-04

Similar Documents

Publication Publication Date Title
JP7755632B2 (ja) 統合的ストレス経路のモジュレーター
CN109641854B (zh) 整合应激通路的调节剂
TWI818929B (zh) 整合應激路徑之調節劑
CN112204009B (zh) 整合应激通路的调节剂
JP7003114B2 (ja) 統合ストレス経路のモジュレーター
JP2021107415A (ja) 統合ストレス経路のモジュレーター
CN112166113A (zh) 整合应激通路的调节剂
HK40110222A (en) Modulators of the integrated stress pathway
HK40044136A (en) Modulators of the integrated stress pathway
HK40044910A (en) Modulators of the integrated stress pathway
HK40044910B (en) Modulators of the integrated stress pathway

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20260526

Address after: California, USA

Patentee after: CALICO LIFE SCIENCES

Country or region after: U.S.A.

Address before: California, USA

Patentee before: CALICO LIFE SCIENCES

Country or region before: U.S.A.

Patentee before: AbbVie Inc.

TR01 Transfer of patent right